(TEVA) Teva Pharma Industries - NYSE
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 36.656m USD | Total Return: 95.7% in 12m
Avg Turnover: 198M
EPS Trend: -19.8%
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 2
Warnings
Altman Z'' -0.40 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Teva Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in Tel Aviv-Yafo, Israel, founded in 1901. It operates a dual business model spanning generic medicines and branded biopharmaceutical products, with a geographic footprint across the United States, Europe, Israel, and other international markets. This combination of generics and specialty drugs is a common industry structure, as generics typically drive high-volume, lower-margin revenue while branded specialty products provide higher margins and help offset pricing pressure on off-patent drugs.
The company produces generic medicines in a wide range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams, as well as sterile products, hormones, high-potency drugs, and cytotoxic substances. It also supplies active pharmaceutical ingredients (APIs) and offers contract manufacturing services, which are typical revenue streams in the pharmaceutical sector, allowing firms to monetize excess manufacturing capacity. In addition, Teva runs an out-licensing platform through which it licenses products to other pharmaceutical companies.
On the branded side, Teva focuses on the central nervous system (CNS), respiratory, and oncology therapeutic areas. Key products include COPAXONE for relapsing forms of multiple sclerosis, AJOVY for the preventive treatment of migraine in adults, AUSTEDO for neurodegenerative and movement disorders such as chorea associated with Huntingtons disease and tardive dyskinesia, and UZEDY for schizophrenia. In oncology, BENDEKA and TREANDA injections are used to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkins lymphoma. Its respiratory portfolio includes ProAir RespiClick, QVAR RediHaler, AirDuo RespiClick, and DuoResp Spiromax.
The company also markets consumer healthcare (OTC) products under brand names such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA. Teva has established collaboration agreements with MedinCell S.A., Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH. It trades on the NYSE under the ticker symbol TEVA and is classified within the Health Care sector under the GICS Pharmaceuticals sub-industry.
- Austedo revenue growth drives branded margins higher
- Copaxone faces continued generic erosion in multiple sclerosis
- Debt reduction plan accelerates amid elevated leverage
| Net Income: 1.56b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.94 > 1.0 |
| NWC/Revenue: 1.03% < 20% (prev 2.23%; Δ -1.21% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.71b > Net Income 1.56b |
| Net Debt (13.4b) to EBITDA (3.27b): 4.11 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.18b) vs 12m ago 1.73% < -2% |
| Gross Margin: 52.06% > 18% (prev 49.17%; Δ 2.89% > 0.5%) |
| Asset Turnover: 44.22% > 50% (prev 43.25%; Δ 0.97% > 0%) |
| Interest Coverage Ratio: 2.51 > 6 (EBIT TTM 2.27b / Interest Expense TTM 905.0m) |
| A: 0.00 (Total Current Assets 13.7b - Total Current Liabilities 13.5b) / Total Assets 40.0b |
| B: -0.33 (Retained Earnings -13.4b / Total Assets 40.0b) |
| C: 0.06 (EBIT TTM 2.27b / Avg Total Assets 39.2b) |
| D: 0.26 (Book Value of Equity 8.23b / Total Liabilities 31.8b) |
| Altman-Z'' = -0.40 = B |
| DSRI: 0.96 (Receivables 3.39b/3.38b, Revenue 17.3b/16.6b) |
| GMI: 0.94 (GM 49.17% / 52.06%) |
| AQI: 0.96 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 1.04 (Revenue 17.3b / 16.6b) |
| TATA: -0.00 (NI 1.56b - CFO 1.71b) / TA 40.0b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of June 24, 2026, the stock is trading at USD 33.21 with a total of 4,486,978 shares traded. Over the past week, the price has changed by -1.42%, over one month by -4.05%, over three months by +15.43% and over the past year by +95.70%.
Current recommended Stop Loss: 31.80 (which is 4.2% or 1.2 ATR below the current price).
Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.
- StrongBuy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.9 | 23.2% |
P/E Trailing = 23.4925
P/E Forward = 15.1745
P/S = 2.1129
P/B = 4.4551
P/EG = 0.8977
Revenue TTM = 17.3b USD
EBIT TTM = 2.27b USD
EBITDA TTM = 3.27b USD
Long Term Debt = 14.0b USD (from longTermDebt, last quarter)
Short Term Debt = 2.61b USD (from shortTermDebt, last quarter)
Debt = 17.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 280.0m
Net Debt = 13.4b USD (calculated: Debt 17.2b - CCE 3.74b)
Enterprise Value = 50.1b USD (36.7b + Debt 17.2b - CCE 3.74b)
Interest Coverage Ratio = 2.51 (Ebit TTM 2.27b / Interest Expense TTM 905.0m)
EV/FCF = 42.75x (Enterprise Value 50.1b / FCF TTM 1.17b)
FCF Yield = 2.34% (FCF TTM 1.17b / Enterprise Value 50.1b)
FCF Margin = 6.76% (FCF TTM 1.17b / Revenue TTM 17.3b)
Net Margin = 9.02% (Net Income TTM 1.56b / Revenue TTM 17.3b)
Gross Margin = 52.06% ((Revenue TTM 17.3b - Cost of Revenue TTM 8.32b) / Revenue TTM)
Gross Margin QoQ = 49.49% (prev 56.36%)
Tobins Q-Ratio = 1.25 (Enterprise Value 50.1b / Total Assets 40.0b)
Interest Expense / Debt = 5.27% (Interest Expense 905.0m / Debt 17.2b)
Taxrate = 15.37% (67.0m / 436.0m)
NOPAT = 1.92b (EBIT 2.27b * (1 - 15.37%))
Current Ratio = 1.01 (Total Current Assets 13.7b / Total Current Liabilities 13.5b)
Debt / Equity = 2.09 (Debt 17.2b / totalStockholderEquity, last quarter 8.23b)
Debt / EBITDA = 4.11 (Net Debt 13.4b / EBITDA 3.27b)
Debt / FCF = 11.47 (Net Debt 13.4b / FCF TTM 1.17b)
Total Stockholder Equity = 7.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.99% (Net Income 1.56b / Total Assets 40.0b)
RoE = 20.70% (Net Income TTM 1.56b / Total Stockholder Equity 7.55b)
RoCE = 10.53% (EBIT 2.27b / Capital Employed (Equity 7.55b + L.T.Debt 14.0b))
RoIC = 6.80% (NOPAT 1.92b / Invested Capital 28.3b)
WACC = 6.70% (E(36.7b)/V(53.8b) * Re(7.75%) + D(17.2b)/V(53.8b) * Rd(5.27%) * (1-Tc(0.15)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.21 | Cagr: 1.63%
[DCF] Terminal Value 77.97% ; FCFF base≈1.01b ; Y1≈1.16b ; Y5≈1.70b
[DCF] Fair Price = 10.46 (EV 25.6b - Net Debt 13.4b = Equity 12.2b / Shares 1.16b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -19.81 | EPS CAGR: -5.37% | SUE: 0.18 | # QB: 0
Revenue Correlation: 94.21 | Revenue CAGR: 4.76% | SUE: 1.31 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.54 | Chg30d=-3.40% | Revisions=-33% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.39 | Chg30d=-18.15% | Revisions=-50% | Analysts=9
EPS current Year (2026-12-31): EPS=2.28 | Chg30d=-2.38% | Revisions=-17% | GrowthEPS=-22.1% | GrowthRev=-3.5%
EPS next Year (2027-12-31): EPS=3.10 | Chg30d=-0.18% | Revisions=+29% | GrowthEPS=+35.6% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: -50%